Fig. 7. Effects of the treatments with lovastatin, fluvastatin and nystatin on the plasma-membrane microdomain localization (A) and TGF-1-induced degradation of TR-II (B) in Mv1Lu cells. Cells were treated with or without lovastatin (1 µM), fluvastatin (1 µM) or nystatin (25 µg/ml) at 37°C for 16 hours or 1 hour, respectively. The treated cells were directly analyzed by sucrose density gradient ultracentrifugation analysis (A) or further incubated with 50 pM TGF- at 37°C for several time periods as indicated (B). Western blot analyses of the sucrose density gradient fractions (A) and of TGF-1-treated cell lysates (B) were performed using anti-TR-II, anti-caveolin-1, anti-TfR-1 and anti--actin antibodies. The open arrowheads indicate the increased amount of TR-II in the fraction as compared with that of the untreated control. The data are representative of a total of three independent analyses; values are mean ± s.d. ^*Significantly higher than that in cells treated without fluvastatin: P<0.05.